Lymphedema Treatment Market Size, Share, Growth Analysis, By End-User(Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Others), By Product(Compression Bandages, Compression Stockings, Pneumatic Compression Devices, Others), By Condition Type(Cancer, Cardiovascular Diseases, Inflammatory Diseases, Others), By Treatment Type(Compression Therapy, Surgery, Drug Therapy, Laser Therapy), By Region - Industry Forecast 2024-2031

Lymphedema Treatment Market size was valued at USD 786.53 million in 2019 and is poised to grow from USD 860.14 million in 2023 to USD 1735.36 million by 2031, growing at a CAGR of 9.5% in the forecast period (2024-2031).

Lymphedema is a disorder characterized by abnormal bodily swelling brought on by lymphocytosis due to lymphatic system dysfunction. 90% of the time, it affects the lower extremity, 10% the upper extremity, and 1% the genitalia. The infection brought on by the parasite Wuchereria bancrofti is the most frequent cause of lymphedema (filariasis). One of the most dreaded and unfortunate side effects of breast cancer treatment is lymphedema. A National Center for Biotechnology Information (NCBI) report states that 40% of women receiving treatment for breast cancer had lymphedema. The increasing incidence of breast cancer, the rising prevalence of lymphedema, the launch of several new products by major market players, and the rising demand for effective goods as a result of technical improvements are the main drivers of the lymphedema treatment market expansion.

According to the United States Department of Health and Human Services, lymphedema, which affects lymph node draining, can develop in cancer patients either at the beginning of the disease or after therapy. For instance, it has been observed that it might happen right away or up to 30 years following breast cancer therapy. In addition, 80% of patients exhibit beginning within 3 years following surgery, with the other 20% developing edema at a 1% per year pace. In addition, a sizable patient population, mostly women, experience lower-limb lymphedema following the management of gynecologic cancer, with vulvar cancer survivors having the highest frequency (37%) and ovarian cancer survivors having the lowest prevalence (7%). Additionally, two years after surgery, the overall incidence of arm lymphedema ranged from 8% to 56%. The American College of Surgeons Oncology Group (ACOSOG) Alliance Z 1071 longitudinal substudy reports that patients in breast cancer trials report a 3-year cumulative incidence of arm edema and arm heaviness. Options for cancer therapy that are very successful and cutting edge help to reduce the likelihood of lymphedema. As a result, the market's key players for cancer therapies are putting a lot of effort into introducing new products.

US Lymphedema Treatment Market is poised to grow at a sustainable CAGR for the next forecast year.